Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide

被引:25
|
作者
Kitasato, Lisa [1 ]
Tojo, Taiki [1 ,2 ]
Hatakeyama, Yuko [2 ]
Kameda, Ryo [1 ]
Hashikata, Takehiro [1 ]
Yamaoko-Tojo, Minako [1 ,3 ,4 ]
机构
[1] Kitasato Univ, Grad Sch Med Sci, Sagamihara, Kanagawa 228, Japan
[2] Kitasato Univ, Sch Med, Dept Cardioangiol, Sagamihara, Kanagawa 228, Japan
[3] Kitasato Univ, Special Dept Cardiac Rehabil & Prevent Cardiovasc, Sch Med, Sagamihara, Kanagawa 228, Japan
[4] Kitasato Univ, Sch Allied Hlth Sci, Dept Rehabil, Minami Ku, Sagamihara, Kanagawa 2520373, Japan
关键词
Atherosclerosis; Endothelial function; Cardiovascular disease prevention; OXIDATIVE STRESS GENERATION; IMPAIRED GLUCOSE-TOLERANCE; CROSS-SECTIONAL RELATIONS; CORONARY-HEART-DISEASE; SENSITIVE K+ CHANNEL; CARDIOVASCULAR-DISEASE; GLYCEMIC CONTROL; NITRIC-OXIDE; RISK-FACTORS; INSULIN-SECRETION;
D O I
10.1186/1475-2840-11-79
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The risk of cardiovascular complication in a diabetes patient is similar to that in a nondiabetic patient with a history of myocardial infarction. Although intensive control of glycemia achieved by conventional antidiabetic agents decreases microvascular complications such as retinopathy and nephropathy, no marked effect has been reported on macrovascular complications or all-cause mortality. Evidence from VADT, ACCORD, and ADVANCE would suggest that glycemic control has little effect on macrovascular outcomes. Moreover, in the case of ACCORD, intensive glycemic control may be associated with an increased risk of mortality. There is sufficient evidence that suggests that postprandial hyperglycemia may be an independent risk factor for cardiovascular disease in diabetes patients. However, there are no prospective clinical trials supporting the recommendation that lowering postprandial blood glucose leads to lower risk of cardiovascular outcomes. Mitiglinide is a short-acting insulinotropic agent used in type 2 diabetes treatment. It has a rapid stimulatory effect on insulin secretion and reduces postprandial plasma glucose level in patients with type 2 diabetes. Because of its short action time, it is unlikely to exert adverse effects related to hypoglycemia early in the morning and between meals. Mitiglinide reduces excess oxidative stress and inflammation, plays a cardioprotective role, and improves postprandial metabolic disorders. Moreover, mitiglinide add-on therapy with pioglitazone favorably affects the vascular endothelial function in type 2 diabetes patients. These data suggest that mitiglinide plays a potentially beneficial role in the improvement of postprandial hyperglycemia in type 2 diabetes patients and can be used to prevent cardiovascular diseases. Although the results of long-term, randomized, placebo-controlled trials for determining the cardiovascular effects of mitiglinide on clinical outcomes are awaited, this review is aimed at summarizing substantial insights into this topic.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] The effect of hyperinsulinemia and hyperglycemia on endothelial function in pregnant patients with type-2 diabetes
    Khurana, Reena
    Meneilly, Graydon S.
    Lim, Kenneth
    Thompson, David
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 103 (03) : E11 - E13
  • [22] Additive Postprandial Glucose-Lowering Effects of Mitiglinide and Sitagliptin in Patients with Type 2 Diabetes Mellitus
    Jin Ah Jung
    Kohei Kaku
    Jae Hyeon Kim
    Jung-Ryul Kim
    Jae-Wook Ko
    Soo-Youn Lee
    Wooseong Huh
    Advances in Therapy, 2013, 30 : 1018 - 1029
  • [23] Fasting and Postprandial Hyperglycemia: Their Predictors and Contributions to Overall Hyperglycemia in Korean Patients with Type 2 Diabetes
    Moon, Jaecheol
    Kim, Ji Young
    Yoo, Soyeon
    Koh, Gwanpyo
    ENDOCRINOLOGY AND METABOLISM, 2020, 35 (02) : 290 - 297
  • [24] Effects of combination therapy with mitiglinide and voglibose on postprandial plasma glucose in patients with type 2 diabetes mellitus
    Konya, Hiroyuki
    Katsuno, Tomoyuki
    Tsunoda, Taku
    Yano, Yuzo
    Kamitani, Mai
    Miuchi, Masayuki
    Hamaguchi, Tomoya
    Miyagawa, Jun-Ichiro
    Namba, Mitsuyoshi
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2013, 6 : 317 - 325
  • [25] Additive Postprandial Glucose-Lowering Effects of Mitiglinide and Sitagliptin in Patients with Type 2 Diabetes Mellitus
    Jung, Jin Ah
    Kaku, Kohei
    Kim, Jae Hyeon
    Kim, Jung-Ryul
    Ko, Jae-Wook
    Lee, Soo-Youn
    Huh, Wooseong
    ADVANCES IN THERAPY, 2013, 30 (11) : 1018 - 1029
  • [26] Effects of acute TUDCA administration on postprandial hyperglycemia and endothelial function
    Walsh, Lauren Kay
    Restaino, Robert
    Manrique, Camila
    Padilla, Jaume
    FASEB JOURNAL, 2016, 30
  • [27] Postprandial hyperglycemia in a national sample of US adults with Type 2 diabetes mellitus
    Erlinger, TP
    Brancati, FL
    DIABETES, 2001, 50 : A213 - A213
  • [28] Postmeal Walking Attenuates Postprandial Hyperglycemia in a Population at Risk for Type 2 Diabetes
    Knurick, Jessica R.
    Johnston, Carol S.
    Gaesser, Glenn A.
    MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2015, 47 (05): : 672 - 672
  • [29] Targeting postprandial hyperglycemia: A comparative study of insulinotropic agents in type 2 diabetes
    Carroll, MF
    Gutierrez, A
    Castro, M
    Tsewang, D
    Schade, DS
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (11): : 5248 - 5254
  • [30] Postprandial Hyperglycemia and Arterial Stiffness Related in Patients with Type-2-Diabetes?
    Kahl, S.
    DIABETOLOGE, 2016, 12 (02): : 122 - 123